Sotac Pharmaceuticals Ltd
Incorporated in 2015, Sotac Pharmaceuticals
Ltd manufactures and sells a wide range of pharmaceutical products[1]
- Market Cap ₹ 105 Cr.
- Current Price ₹ 95.1
- High / Low ₹ 140 / 95.1
- Stock P/E 18.2
- Book Value ₹ 53.3
- Dividend Yield 0.11 %
- ROCE 12.6 %
- ROE 10.3 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 34.7% CAGR over last 5 years
Cons
- Company has a low return on equity of 13.0% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of Nifty SME Emerge
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 29 | 49 | 77 | 104 | 97 | 101 | |
| 27 | 47 | 70 | 95 | 83 | 83 | |
| Operating Profit | 2 | 1 | 7 | 9 | 14 | 18 |
| OPM % | 7% | 3% | 10% | 8% | 14% | 18% |
| 0 | 0 | 1 | 0 | 4 | 0 | |
| Interest | 0 | 1 | 2 | 2 | 3 | 4 |
| Depreciation | 1 | 3 | 2 | 3 | 4 | 5 |
| Profit before tax | 0 | -2 | 4 | 4 | 11 | 9 |
| Tax % | 75% | 15% | 42% | 10% | 17% | 28% |
| 0 | -2 | 2 | 4 | 9 | 6 | |
| EPS in Rs | 0.39 | -10.30 | 3.58 | 3.87 | 7.27 | 5.22 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 4% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 16% |
| 3 Years: | 10% |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 35% |
| 3 Years: | 31% |
| TTM: | -25% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -7% |
| 1 Year: | -24% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 13% |
| Last Year: | 10% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 8 | 11 | 11 | 11 |
| Reserves | 1 | 0 | 11 | 34 | 42 | 48 |
| 13 | 17 | 22 | 25 | 44 | 38 | |
| 14 | 15 | 32 | 35 | 27 | 37 | |
| Total Liabilities | 30 | 35 | 74 | 105 | 124 | 133 |
| 16 | 17 | 26 | 36 | 49 | 50 | |
| CWIP | 0 | 0 | 0 | 5 | 0 | 2 |
| Investments | 0 | 0 | 0 | 2 | 4 | 3 |
| 14 | 18 | 48 | 63 | 72 | 79 | |
| Total Assets | 30 | 35 | 74 | 105 | 124 | 133 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 0 | -0 | 8 | -16 | -4 | 17 | |
| -12 | -3 | -12 | -20 | -14 | -7 | |
| 11 | 3 | 13 | 29 | 16 | -10 | |
| Net Cash Flow | -0 | -0 | 10 | -6 | -2 | -0 |
| Free Cash Flow | -10 | -3 | 0 | -34 | -16 | 9 |
| CFO/OP | 17% | 8% | 134% | -168% | -26% | 106% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 89 | 44 | 70 | 92 | 128 | 119 |
| Inventory Days | 40 | 45 | 87 | 83 | 108 | 153 |
| Days Payable | 194 | 121 | 162 | 132 | 101 | 154 |
| Cash Conversion Cycle | -66 | -32 | -5 | 43 | 136 | 118 |
| Working Capital Days | -79 | -44 | -40 | 47 | 63 | 65 |
| ROCE % | -5% | 10% | 15% | 13% |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Tablet revenue share of total revenue (standalone) % of total revenue ・Standalone data |
|
||||
| Installed tablet capacity - Sotac Healthcare (subsidiary, Beta-Lactam unit) crore tablets/year ・Standalone data |
|||||
| Number of corporate clients (contract manufacturing) clients |
|||||
| Number of domestic states served (India) states |
|||||
| Number of export countries served countries |
|||||
| Number of permanent employees (Sotac Pharma, parent) employees ・Standalone data |
|||||
| Installed tablet capacity - Sotac Pharmaceuticals (parent, Non-Beta-Lactam unit) crore tablets/year ・Standalone data |
|||||
| Product portfolio size (Sotac Group) products |
|||||
Extracted by Screener AI
Documents
Announcements
-
Bagging/Receiving of orders/contracts
23 July 2026 - Sotac Pharmaceuticals received Rs. 97.57 lakh order from Intas Pharmaceuticals for formulations, to be supplied by November 5, 2026.
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
9 July 2026 - Filed Regulation 74(5) certificate for quarter ended June 30, 2026; no dematerialization or rematerialization received.
-
Dividend
26 May 2026 - Board approved FY26 audited standalone and consolidated results, and recommended Rs.0.20 final dividend per share.
-
Outcome of Board Meeting
26 May 2026 - Board approved FY26 audited results, recommended Rs 0.20 final dividend, and reported unmodified audit opinion.
-
Structural Digital Database
25 May 2026 - Submitted SDD compliance certificate for FY ended March 31, 2026; 9 events captured, no non-compliance.
Business Overview:[1]
SPL specializes in manufacturing a broad range of pharmaceutical products across various therapeutic areas, including anti-diabetic, anti-psychotic, vitamins, minerals, iron supplements, anti-cold, anti-allergic, dermatological treatments, antacids, anti-ulcer (PPI), anti-emetics, cardiac, antihypertensives, analgesic, antipyretic, anti-inflammatory, antibacterial, antiviral, general antibiotics (β-lactams and non-β-lactams), antifungal, and cephalosporins.